128 results on '"van Vugt, Marcel A.T.M."'
Search Results
2. EXO1 protects BRCA1-deficient cells against toxic DNA lesions
3. FIRRM/C1orf112 is synthetic lethal with PICH and mediates RAD51 dynamics
4. WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study
5. MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells
6. When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers
7. Genomic instability, inflammatory signaling and response to cancer immunotherapy
8. RAD52-dependent mitotic DNA synthesis is required for genome stability in Cyclin E1-overexpressing cells
9. The Fanconi anemia core complex promotes CtIP-dependent end-resection to drive homologous recombination at DNA double-strand breaks
10. Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma
11. Replication stress: Driver and therapeutic target in genomically instable cancers
12. Data from Toward Molecular Imaging–Driven Drug Development in Oncology
13. Supplementary Figure 7 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment
14. Download Supplementary Movie File from Toward Molecular Imaging–Driven Drug Development in Oncology
15. Data from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment
16. Supplementary Figure 5 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment
17. Supplementary Figure 6 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment
18. Supplementary Figure 4 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment
19. Supplementary Figure 2 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment
20. Supplementary Figure 1 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment
21. Supplementary Figure 3 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment
22. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions
23. The FIGNL1-interacting protein C1orf112 is synthetic lethal with PICH and mediates RAD51 retention on chromatin
24. Processing DNA lesions during mitosis to prevent genomic instability
25. MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells
26. Adavosertib in combination with carboplatin in advanced TP53-mutated platinum-resistant ovarian cancer.
27. Sister chromatid exchanges induced by perturbed replication can form independently of BRCA1, BRCA2 and RAD51
28. MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling
29. Sister chromatid exchanges induced by perturbed replication can form independently of BRCA1, BRCA2 and RAD51
30. Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome
31. Sister chromatid exchanges induced by perturbed replication are formed independently of homologous recombination factors
32. Publisher Correction:Elongation factor ELOF1 drives transcription-coupled repair and prevents genome instability (Nature Cell Biology, (2021), 23, 6, (608-619), 10.1038/s41556-021-00692-z)
33. The H3.3K27M oncohistone affects replication stress outcome and provokes genomic instability in pediatric glioma
34. MYC promotes immune-suppression in TNBC via inhibition of IFN signaling
35. An mRNA expression-based signature for oncogene-induced replication-stress
36. Molecular imaging for monitoring treatment response in breast cancer patients
37. Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by Artificial Transcription Factors
38. The role of ATM and 53BP1 as predictive markers in cervical cancer
39. Abstract 6229: MDM2 inhibitors sensitize testicular cancer models to mTORC1/2 inhibitors and cisplatin
40. Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities
41. Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment
42. Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity
43. Inflammatory signaling in genomically instable cancers
44. Cyclin E expression is associated with high levels of replication stress in triple-negative breast cancer
45. Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma
46. Never tear us a-PARP: Dealing with DNA lesions during mitosis
47. Shutting down the power supply for DNA repair in cancer cells
48. Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine
49. Breaking the DNA damage response to improve cervical cancer treatment
50. Abstract B19: Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.